clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00211939 |
P6099 | clinical trial phase | phase IV clinical trial | Q42825046 |
P17 | country | United States of America | Q30 |
P582 | end time | 2006-12-01 | |
P1050 | medical condition | arteriosclerosis | Q184559 |
hyperparathyroidism | Q1344835 | ||
calcinosis | Q239027 | ||
P2899 | minimum age | 18 | |
P1132 | number of participants | 203 | |
P4844 | research intervention | calcium oxalate | Q412399 |
sevelamer | Q904153 | ||
P859 | sponsor | Nabi Biopharmaceuticals | Q6956843 |
P580 | start time | 2005-01-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) |
Search more.